1. Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST)
Figure 1 | Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST). a | Development of imatinib in CML. A new drug application was submitted 2 years and 9 months after the first treatment of a patient with CML, triggering the FDA approval of imatinib within 3 months of the initial application. b | Development of imatinib in GIST. Hirota and co-authors171 first discovered the somatic gain of function mutations of KIT in patients with GIST. A case report18 and the outstanding results of the phase I13 and II trials172 of imatinib led to the rapid launch of two phase III trials of this agent. The first off-target effect of imatinib was demonstrated on NK cells in 2004 (Ref. 69). PKCi, protein kinase C inhibitor; TKI, tyrosine kinase inhibitor.
Kroemer, G. et al. (2016) Immunological off-target effects of imatinib
Nat. Rev. Clin. Oncol. doi: /nrclinonc